# Study of XNW5004 Tablets in Advanced Prostate Cancer

> **NCT07730580** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 242 (estimated)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone
- **DRUG:** XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone
- **DRUG:** XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID
- **DRUG:** XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD
- **DRUG:** XNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone
- **DRUG:** XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks.
- **DRUG:** Subsequent development plans will be determined based on preliminary study results.

## Key facts

- **NCT ID:** NCT07730580
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730580, "Study of XNW5004 Tablets in Advanced Prostate Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*